PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

Report Back from SGO 2023: What’s New in Ovarian Cancer?Подробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

PARP inhibitor rechallenging in ovarian cancerПодробнее

Overcoming resistance to PARP inhibition in ovarian cancerПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

PARP Inhibitors: 2023 UpdatesПодробнее

PARP inhibitors for ovarian cancerПодробнее

Updates in PARP inhibition for ovarian cancerПодробнее

PARP inhibitors and ovarian cancerПодробнее

A Webinar on PARP Inhibitors in Epithelial Ovarian CancerПодробнее

Updates in Treatment of Ovarian Cancer: PARP InhibitorsПодробнее

An Overview of PARP Inhibitors in Ovarian CancerПодробнее

Report Back from SGO 2023: What’s New in Uterine Cancer?Подробнее

Ovarian Cancer Symposium 2021: Session 4 PARP InhibitorsПодробнее

Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancerПодробнее

Novel Therapeutics in Ovarian Cancer: What to WatchПодробнее

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian CancerПодробнее

PARP Inhibitor Trial UpdatesПодробнее

Report Back from SGO: What’s the Latest in Ovarian Cancer?Подробнее